Table of contents
Jakavi is a medicine used to treat the following conditions:
- splenomegaly (enlarged spleen) or other disease-related symptoms such as fever, night sweats, bone pain and weight loss in adults who have myelofibrosis. Myelofibrosis is a disease in which the bone marrow becomes very dense and rigid and produces abnormal, immature blood cells.
- polycythaemia vera in adults in whom the medicine hydroxycarbamide (also known as hydroxyurea) does not work or causes unacceptable side effects. In polycythaemia vera, too many red blood cells are produced, which can cause reduced blood flow to the organs due to ‘thickening’ of the blood and occasionally the formation of blood clots.
- acute or chronic graft-versus-host disease (when transplanted cells attack the body) in people aged 12 and older who have had a transplantation and for whom corticosteroids or other systemic therapies (treatments given by mouth or injection) did not work well enough.
Jakavi contains the active substance ruxolitinib.
Jakavi : EPAR - Summary for the public (PDF/153.32 KB)
First published: 04/10/2012
Last updated: 18/05/2022
Jakavi : EPAR - Risk-management-plan summary (PDF/75.9 KB)
First published: 04/08/2021
Last updated: 17/01/2023
|Agency product number||
ruxolitinib (as phosphate)
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Novartis Europharm Limited
|Date of issue of marketing authorisation valid throughout the European Union||
05/01/2023 Jakavi - EMEA/H/C/002464 - IB/0063
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.
Polycythaemia vera (PV)
Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.
Graft versus host disease (GvHD)
Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).